Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 38.58M P/E - EPS this Y 39.00% Ern Qtrly Grth -
Income -87.68M Forward P/E -0.78 EPS next Y 1.20% 50D Avg Chg -12.00%
Sales 15.53M PEG - EPS past 5Y - 200D Avg Chg -24.00%
Dividend N/A Price/Book 0.46 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.50 Quick Ratio 5.68 Shares Outstanding 72.58M 52W Low Chg 7.00%
Insider Own 20.39% ROA -36.64% Shares Float 37.90M Beta 2.34
Inst Own 60.53% ROE -89.48% Shares Shorted/Prior 657.21K/365.60K Price 0.90
Gross Margin - Profit Margin - Avg. Volume 219,895 Target Price 4.00
Oper. Margin -942.67% Earnings Date May 7 Volume 84,169 Change 2.09%
About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Aligos Therapeutics, Inc. News
04/30/24 Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
04/25/24 Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
04/25/24 Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
04/09/24 Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
04/03/24 Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
03/27/24 Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
03/27/24 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
03/18/24 Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
03/14/24 Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
03/12/24 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
04:05 PM Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
02/26/24 Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
02/20/24 Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
02/13/24 Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
09:40 AM Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
12/07/23 Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
11/24/23 13 Stocks Insiders are Buying Now
11/20/23 Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
11/13/23 Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
11/10/23 Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
ALGS Chatroom

User Image PensionPulse Posted - 3 days ago

$ALGS $MDGL $VKTX $SGMT Tribute to Dr. Stephen Harrison (1969-2024), a giant in the field of hepatology: https://easl.eu/news/obituarystephenharrison/

User Image rp6577 Posted - 3 days ago

$ALGS waking up! $XBI

User Image Stock_Titan Posted - 04/30/24

$ALGS Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 https://www.stocktitan.net/news/ALGS/aligos-therapeutics-to-announce-1st-quarter-2024-financial-results-b5sjiy8v2ke7.html

User Image JoshThe3rd Posted - 04/29/24

$ALGS starting to connect some dots here w Roche owning 14%. https://twitter.com/DueDoctor/status/1783220679305015352

User Image I_am_retail_investor Posted - 04/27/24

$ALGS - So far in clinical trials, Blatt said ALG-055009 is showing up to 100-fold more potency than Rezdiffra. He added that, in contrast to Rezdiffra, the drug has linear and non-variable pharmacokinetics, “so it’s very well controlled.” https://www.biospace.com/article/5-promising-mash-therapies-that-could-follow-madrigal-s-rezdiffra-/

User Image DonCorleone77 Posted - 04/25/24

$ALGS Aligos Therapeutics to present data on ALG-097558 at ESCMID Aligos Therapeutics announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases, or ESCMID, 2024, being held April 27-30 in Barcelona, Spain. The presentation highlights ALG-097558 Phase 1 data showing that single and multiple doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.

User Image Stock_Titan Posted - 04/25/24

$ALGS Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study https://www.stocktitan.net/news/ALGS/aligos-therapeutics-presents-positive-clinical-data-at-escmid-2024-fhrptuoa7khw.html

User Image Stock_Titan Posted - 04/25/24

$ALGS Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD https://www.stocktitan.net/news/ALGS/aligos-therapeutics-mourns-the-passing-of-mash-industry-leader-iiaa6vra5uuz.html

User Image I_am_retail_investor Posted - 04/22/24

$ALGS - I like the $80s show, but prefer the $90s. Get’r done, Aligos, stop with the putzing.

User Image Quantumup Posted - 04/22/24

BofA #MASH Primer~Sees attractive investment opportunity Says Multifactorial nature of #MASH supports multiple MoAs $MDGL $IVA $VKTX $ETNB AKRO $ALGS IONS SGMT LLY NVO PFE NGM REGN ALNY ARWR GILD ALT 📝's space has heated up, w/ >30 players Ests #MASH mkt = $23B by '35:

User Image Happy_Feet19 Posted - 04/19/24

$ALGS Anybody know about the SEC filing related to the de-lisiting (If they received anything from SEC)? I don't see anything related to delisting. If someone located it can you post the SEC date on their website

User Image Bwnuts Posted - 04/18/24

$ALGS this will retest ATL for sure.

User Image Skeetz99 Posted - 04/17/24

$ALGS $ALGS The Reverse split is stated as a consideration and its most likely for Nasdaq compliance reasons. There isn’t anything definitive that it will happen (and they won’t make any decisions until the Annual meeting in late June). See below: “To grant the Company’s Board of Directors authority to amend the Amended and Restated Certificate of Incorporation and effect a reverse stock split of the Company’s voting and non-voting common stock within a range of not less than 1-for-5 and not more than 1-for-30, if the Company’s Board of Directors deems it within the best interests of the Company (the “Reverse Stock Split Amendment”)”

User Image Bwnuts Posted - 04/17/24

$ALGS my question is who got wind of the filing the day prior? clearly the info was leaked.

User Image Bwnuts Posted - 04/17/24

$ALGS crazy how a stock can go from promising to absolute garbage in just a few days.

User Image Nanu108 Posted - 04/16/24

$ALGS I'm In.

User Image I_am_retail_investor Posted - 04/16/24

$ALGS - it was a good chart #uglydayonlowishvolume

User Image Barsofgreen Posted - 04/16/24

$ALGS buy at .60-.65

User Image Logout Posted - 04/16/24

$ASMB $ALGS

User Image Stock_Titan Posted - 04/09/24

$ALGS Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 https://www.stocktitan.net/news/ALGS/aligos-therapeutics-to-participate-in-the-piper-sandler-spring-9716s15xisp8.html

User Image MoCoHai Posted - 04/09/24

$ALGS still waiting for the $1,3 Mio funding news by NIH

User Image MoCoHai Posted - 04/09/24

$ALGS insider purchase of $10Mio just a few months ago!

User Image MoCoHai Posted - 04/09/24

$ALGS enough fundings until end of 2025!

User Image MoCoHai Posted - 04/08/24

$ALGS topline data end of the month!

User Image I_am_retail_investor Posted - 04/08/24

$ALGS - great chart and nice support, market is finally catching up on this small cap undervalued!

User Image Bwnuts Posted - 04/08/24

@sportymn11 $ALGS much better play. It's doing what $IMRX will attempt to do many months down the road.

User Image Doozio Posted - 04/06/24

$ALGS after a Thursday 🐑 yo go 🧠⏰♾️ FRYday close

User Image Bwnuts Posted - 1 month ago

$IMRX go check out $ALGS. Chart fell out of bed and went to the basement for a long long time. It’s just finally reemerging. If $IMRX doesn’t reverse soon (catalyst or shorts leave it alone or both) that’s what you’re in for.

User Image rp6577 Posted - 1 month ago

$ALGS looks like it is going to burst through that recent high $XBI

User Image Doozio Posted - 1 month ago

$ALGS chop chop Thursday 🐑 n huckleberries in 🧠⏰

Analyst Ratings
Piper Sandler Overweight Jan 17, 23
Piper Sandler Overweight Jan 6, 23
Jefferies Buy Jan 6, 23
SVB Leerink Market Perform Nov 3, 22
SVB Leerink Market Perform May 5, 22
SVB Leerink Outperform Mar 23, 22
Piper Sandler Neutral Mar 23, 22
Piper Sandler Overweight Mar 11, 22
SVB Leerink Outperform Mar 11, 22